On Wednesday, Shares of Blueprint Medicines Corp (NASDAQ:BPMC), added 3.29% and now trading at $43.36 in the current trading session. The current trading range of the stock ranges between $42.00 and $43.40.
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, recently declared the closing of its formerly declared underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $40.00 per share, counting the exercise in full by the underwriters of their option to purchase additional shares of common stock. Blueprint Medicines estimates net proceeds from the offering will be about $215.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Goldman, Sachs & Co., Morgan Stanley and Cowen and Company acted as joint book-running managers for the offering. Raymond James is acting as co-manager for the offering.
A registration statement on Form S-3 (File No. 333-216573) regardingthese securities has been formerly filed with and declared effective by the Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.
Analyst recommendation for this stock stands at 1.60.